NCT06183307View on ClinicalTrials.gov

Effects of Nattokinase on Inflammation and Cardiovascular Risk Markers in Patients With Dyslipidemia

NARecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

August 3, 2024

Primary Completion Date

December 20, 2025

Study Completion Date

July 31, 2026

Conditions
Cardiovascular DiseasesDyslipidemiasInflammation
Interventions
DIETARY_SUPPLEMENT

Nattokinase

Participants will receive 1 capsule per day, providing the active nattokinase daily, at a dosage of 100mg, standardized at 2,000 Fibrinolytic Units for 2 months

DIETARY_SUPPLEMENT

Placebo

The placebo group will receive 1 capsule per day with 100mg containing corn starch for 2 months.

Trial Locations (1)

22260050

RECRUITING

Denise Mafra, Rio de Janeiro

All Listed Sponsors
collaborator

Conselho Nacional de Desenvolvimento Científico e Tecnológico

OTHER_GOV

collaborator

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.

OTHER_GOV

collaborator

Rio de Janeiro State Research Supporting Foundation (FAPERJ)

OTHER_GOV

lead

Universidade Federal Fluminense

OTHER